

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria Virginia 22313-1450

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/781,577	02/12/2001		Irene E. Kochevar	10284-018001	9723	
21874	7590	03/14/2005		EXAM	EXAMINER .	
EDWARD:	S & ANC	GELL, LLP	BARRETT, THOMAS C			
P.O. BOX 5 BOSTON, 1)5	ART UNIT	PAPER NUMBER		
200.01, 1 02200				3738		
				DATE MAILED: 03/14/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

8	M
U	1

Advisory Action

Application No.	Applicant(s)	
09/781,577	KOCHEVAR ET AL.	
Examiner	Art Unit	
Thomas C. Barrett	3738	

	33.7 37,31.7					
Before the Filing of an Appeal Brief	Examiner	Art Unit				
	Thomas C. Barrett	3738				
The MAILING DATE of this communication appe	ears on the cover sheet with the d	correspondence add	ress			
THE REPLY FILED <u>17 November 2004</u> FAILS TO PLACE THI	S APPLICATION IN CONDITION F	OR ALLOWANCE.				
 The reply was filed after a final rejection, but prior to filing applicant must timely file one of the following replies: (1) application in condition for allowance; (2) a Notice of Application (RCE) in compliance time periods: 	an amendment, affidavit, or other peal (with appeal fee) in complianc with 37 CFR 1.114. The reply mu	evidence, which plac e with 37 CFR 41.31;	es the or (3) a			
a) The period for reply expires months from the mailing of		- 6 1				
b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b)	an SIX MONTHS from the mailing date o	f the final rejection.				
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f		NOT KEFET WAS FILE	D WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	n fee under 37 as set forth in (b)			
2. The reply was filed after the date of filing a Notice of Approximate was filed on 17 November 2004. A brief in compliance with the Notice of Appeal (37 CFR 41.37(a)), or any extension Notice of Appeal has been filed, any reply must be filed AMENDMENTS.	vith 37 CFR 41.37 must be filed with thereof (37 CFR 41.37(e)), to avo	hin two months of the ap	e date of filing			
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	f, will not be entered	because			
 (a) ☐ They raise new issues that would require further co (b) ☐ They raise the issue of new matter (see NOTE below) (c) ☐ They are not deemed to place the application in be 	ow);		the issues for			
appeal; and/or (d) They present additional claims without canceling a		ejected claims.				
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.			(DTOL 204)			
4. The amendments are not in compliance with 37 CFR 1.		ompliant Amendmen	(PTOL-324).			
 5. Applicant's reply has overcome the following rejection(s 6. Newly proposed or amended claim(s) would be a 		, timely filed amendn	nent canceling			
the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro-		vill be entered and an	explanation of			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration:		•				
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e). 						
The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).						
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after	entry is below or atta	ched.			
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application	in condition for allowa	ance because:			
12. Note the attached Information Disclosure Statement(s).	. (PTO/SB/08 or PTO-1449) Paper	No(s)	1			
13. Other:		Thomas	guilf			
		Thomas C. Barrett Examiner Art Unit: 3738	V			

Continuation of 3. NOTE: the limitation "without producing substantial thermal damage" requires further consideration.

Continuation of 11. does NOT place the application in condition for allowance because: The Applicant argues "In the Khadem Declaration, an exogenous protein substrate concentration of at least 1% is described as a critical ingredient of photoactivable compositions for use in tissue bonding. Thus, as stated by Dr. Hamblin and as supported by the documentary evidence provided herein, the description in Column 7 lines 18-30 and Table 2 of Khadem lack enablement for the claimed methods and the remaining disclosure in Khadem does not fill the gap." However, as noted in the prior action "The declaration states, "it is my opinion, as one of ordinary skill in the art, who has read the Khadem patent, that portions of the patent other than column 7 lines 18-30 cannot be relied upon for additional instruction because they are solely intended for methods that require application of an exogenous substrate". Therefore the declaration admits the "four sentences" are directed to methods that do not require application of exogenous substrates." and therefore the prior art is enabled. Furthermore, regarding the Khadem declaration, column 7 lines 18-30 of the prior cited Khadem reference also discloses "Such methods utilize the peptides or proteins located naturally within the tissue area as in situ protein containing compositions." Contrary to the Applicant's argument Khadem never declares the protein used to be exogenous protein as defined in the present application. Therefore the Khadem declaration does not show the Khadem patent to lack enablement.